Emerging biotech Adaptam Therapeutics has raised €3 million in pre-seed funding to advance a new class of cancer immunotherapies that target immunosuppressive myeloid cells, a key driver of resistance in solid tumors.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?